Immunostimulators induce granulocyte/macrophage colony-stimulating activity and block proliferation in a monocyte tumor cell line by unknown
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The monocyte/macrophage  is the normal producer in marrow  and blood of 
colony-stimulating activity (CSA) required for progenitor cells  to differentiate 
into granulocytes and monocytes in culture (1-3). Bacterial lipopolysaccharide 
(LPS)  activates macrophages  to increased  CSA  production  (3-5), as well as 
synthesis and release of various enzymes,  and nonspecific toxicity for tumor 
cells (6-8). Other activating agents  associated with increased CSA  levels in 
monocyte populations include dextran sulfate (9) and polyinosinic-polycytidylic 
acid (5). 
LPS and other macrophage  activators specifcally inhibit the growth of  tumor 
cell lines of the monocyte  series without affecting other hematopoietic tumor 
types-erythroleukemia,  mastocytoma, T lymphoma,  myelomas, or  fibrosarcoma 
(10, 11). We  describe here induction of  CSA  in monocyte line PU5-1.8, specifi- 
cally by immunostimulators  that block proliferation of  tumor cells. 
Methods  and  Materials 
PU5-1.8 Cell  Line.  Monocyte  cell  line  PU5-1.8,  derived  from  a spontaneous tumor  in  a  BALB/c 
mouse, actively  phagocytoses  zymosan and latex  beads,  bears  receptors  for  immunoglobulin and 
complement, secretes  lysozyme (11),  phagocytoses  sheep erythrocytes,  and kills  tumor targets  in 
the presence  of  specific  antisera.  Cells  grow in  RPMI 1640  medium (Grand Island  Biological  Co., 
Grand Island,  N.Y.) containing  10% fetal  calf  serum with a doubling  time of  16-20  h. 
Substances Tested for  Induction ofCSA.  Dialyzed  latex  beads  0.81  #m diameter,  LPS (Salmo- 
nella typhosa W0901, Difco  Laboratories,  Detroit,  Mich.),  tuberculin  purified  protein  derivative 
(PPD) (gift  from Dr. A. Gray, Merck Sharp & Dohme, West Point,  Pa.),  Mycobacterium Bacillus 
Calmette-Gudrin (BCG) (Tice  strain,  University  of  Illinois,  Chicago),  zymosan, dextran sulfate 
(tool  wt.  500,000),  dibutyryl  cyclic  AMP (Sigma  Chemical Co.,  St.  Louis,  Mo.),  and  silica  (gift  from 
Dr. B. Bloom, Albert  Einstein  College  of  Medicine,  Bronx, N.Y.) were dissolved  or  suspended in 
phosphate-buffered  saline,  pH 7.4.  Phorbol  myristic  acetate  (Consolidated  Midland Corp.,  Brews- 
ter,  N.Y.) was dissolved  in  ethanol.  Lipid  A was derived  from LPS by mild acid  hydrolysis  (12), 
and free  polysaccharide  obtained  by hydrolysis  in 1% acetic  acid  at  100°C  for  2h. 
Assay for CSA  (13).  Mouse bone marrow cells  (7.5  x 104)  were suspended in  1  ml 0.3% Difco 
agar culture  medium containing  enriched McCoy's medium plus  10% fetal  calf  serum. PU5-1.8 
conditioned  medium was assayed at  0.1  ml. Colonies  (>40  cells  per aggregate)  and  clusters  (3-40 
cells  per  aggregate)  were  scored  after  5-7  days.  For  maximum intracellular  CSA, cell  pellets  were 
suspended in  saline  to  the  original  volume  and  lysed  by  two  cycles  of  freeze  thaw. Supernates were 
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Fro.  1.  Induction of CSA in PU5-1.8 cells by LPS. A. Cumulative production. Cultures at 3 
x  105 cells/ml were incubated with 1 pg/ml LPS, and supernates assayed at various times 
for CSA (4-  1 SEM). PU5-1.8 cultures without LPS reached 32  x  105 cells/ml after 3 days; 
these supernates did not contain CSA. B. Incremental production. Cultures were initiated at 
3 x  10  s cells/ml, 1/~g/ml LPS. At day 1, supernate was collected and cells reincubated with 
the same volume of fresh medium containing 1/~g/ml LPS. This was repeated at day 2 and 
day 3. CSA secreted from day 0 to 1, 1 to 2, 2 to 3, and 3 to 4 is shown. In parallel, cells were 
incubated 1 day with LPS, centrifuged, washed once and reincubated 1 or 2 days without 
LPS (dashed lines). Continual presence of inducer is necessary for maximal production of 
CSA. 
dialyzed  extensively  to  remove  actinomycin  D or  puromycin  before  assay  for  CSA. Control  cultures 
received  drugs at the end of  incubation with LPS and were similarly  dialyzed. 
Results 
Kinetics of CSA Production by PU5-1.8 Cells in the Presence of LPS.  PU5- 
1.8 cells were incubated with 1 /~g/ml  LPS which inhibited their growth more 
than 90%. Supernates of untreated cultures did not contain CSA. Small amounts 
of CSA were detected by 6 h incubation with LPS (Fig. 1 A). Supernates of PU5- 
1.8 treated with LPS for 24 h caused colony formation with plateau levels of CSA 
reached after 3-4 days. The plateau represented cessation of CSA synthesis, not 
steady-state  synthesis  and  decay,  since the daily production  of CSA declined 
after  the  second  day  and  was  undetectable  after  the  third  day  (Fig.  1  B). 
Colonies contained  granulocytes and macrophages,  similar to that  stimulated 
by WEHI-3 CSA (14). 
CSA of cell lysates was less than 40% that of the corresponding  supernates 
from  6  h  to  4  days of LPS treatment.  Lysates did  not  contain  inhibitors  of 
granulopoiesis; they did not interfere with colony formation stimulated by CSA 
from WEHI-3, a myelomonocytic leukemia cell line secreting CSA constitutively 
(14). Although PU5-1.8 cell growth was inhibited during incubation with LPS, 
there was less than 10% cell death by trypan blue (11). Induced CSA appears to 
be actively secreted. Synthesis of lysozyme, continuously secreted by PU-5-1.8, 
was not affected or was slightly enhanced during  LPS treatment  (11); overall 
protein synthesis was partially inhibited (12). Actinomycin D at 0.01/~g/ml or 3 
/~g/ml  puromycin  during  LPS treatment  blocked CSA  production  more  than 
80%, implying a requirement for RNA and protein synthesis. Concentrations of 
colchicine (0.1/~g/ml) and mitomycin C (1/~g/ml) that inhibit PU51.8 growth did 
not interfere with LPS induction of CSA. 
Dose-Response  of LPS.  LPS at 0.001  /~g/ml  caused 40% inhibition of tumor 
cell  growth  but no  activation  of CSA  (Fig.  2).  0.01  /~g/ml  LPS caused  some 
significant production of CSA. Maximal induction occurred with 1 pg/ml, which RALPH,  BROXMEYER,  AND  NAKOINZ  BRIEF  DEFINITIVE  REPORT  613 
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FIG.  2.  Dose response of CSA induction by LPS. Cultures were initiated at 2 x  10  5 cells/ml 
plus final concentrations of LPS. Aider 2 days, tumor cells were counted (percent inhibition 
of growth shown) and supernate CSA determined. Control medium, medium incubated 2 
days with 1 or 10 ~g/ml LPS, and 2 days' control cultures of PU5-1.8 to which i  or 10 ~g/ml 
LPS  was  added  when  preparing  supernates  had  only background  levels  of  CSA  (8-14 
clusters). 
blocked tumor cell growth almost completely. Lower CSA of cultures incubated 
with 10 ~g/ml LPS may not represent high dose inhibition of CSA formation. 
This  LPS  concentration  partially  inhibits  colony  formation  stimulated  by 
WEHI-3 CSA.  PU5-1.8 cells may produce a  factor without stimulation  which 
requires LPS for CSA activity.  Cells were incubated 2 days without LPS, and 
supernate  was  prepared  immediately  after  addition  of the  drug.  This  was 
inactive. Thus tumor cells must be in contact with LPS for induction. 
Other Macrophage-Active Agents Which Induce CSA.  Zymosan, BCG, PPD 
tuberculin derivative from Mycobacterium,  LPS, and derived lipid A specifically 
inhibit growth of PU5-1.8 cells but not other hematopoietic tumor lines in culture 
(11).  CSA  is  induced  in  PU5-1.8  cells  by all  of these  macrophage-activating 
substances  that  inhibit  growth  of PU5-1.8,  as  well as  by phorbol  myristate 
(Table I). Dextran sulfate, latex beads actively phagocytosed by the monocyte 
cells (11), and alkali-treated LPS do not inhibit PU5-1.8 growth or induce CSA. 
Not all conditions of tumor cell cytostasis lead to CSA production.  Reversible 
inhibition of cell growth by high concentrations of thymidine or cyclic AMP, or 
by incubating cells without serum did not induce CSA. 
Granulocyte  Inhibitor  of Constitutive  CSA  Production.  Human  granulo- 
cytes contain an activity that inhibits production of CSA by human and murine 
monocytes, CSA-producing cells resident in the marrow and by murine, WEHI-3 
cells, (13). Granulocyte extract, at concentrations which inhibit WEHI-3 consti- 
tutive production more than 50%, had no effect on induction of CSA when added 
to PU5-1.8 cells together with LPS (three experiments). 
Discussion 
Induction of CSA in PU5-1.8 tumor line is similar to that with normal mouse 
macrophages (4) and human monocytes (5) in that 10-100 ng/ml LPS is effective, 
and requires several days for maximal stimulation.  This is characteristic of the 
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TABLE  I 
Induction  of CSA in PU5-1.8 by Macrophage-Active Agents 
Inhibition  of 
Agent  Concentration  CSA (colonies) 
PU5-1.8 growth 
( ~g/ml)  % 
0  0 
1  90  55 ±  8 
10  98  12 _~  2 
1  22  0 
10  44  0 
100  53  0 
10  68  12 _~  4 
50  92  18 ±  3 
10~/ml  104}  14 ±  2 
50  87  58 ±  10 
100  90  9  ±  1 
Phorbel myristate  0.01  11  0 
0.1  53  17 x  3 
1  59  27 ±  3 
Dextran sulfate  1  0  0 
10  0  0 
i00  0  0 
1,000  44  0 
DMSO*  2%  60  0 
Silica  200  90  0 
Latex beads  5 × 10~/ml  0  0 
Dibutyryl cAMP  I0  -~ M  79  0 
10 ~ M  33  0 
10  -s M  89  0 
87  0 
None 
LPS 
Lipid A 
Alkali LPS 
PPD 
BCG 
Zymosan 
Thymidine 
No serum 
Drugs were added as shown to PU5-1.8 cultures initiated at 2 ×  10  ~ cells/ml. After a 3-day incubation. 
tumor cells were counted  and CSA  in supernates determined as in Fig.  1.  Control culture medium 
containing these concentrations of drugs (except phorbel myristate) neither caused colony formation, 
nor inhibited the activity of preformed CSA in the assay system.  Cell culture and control solutions of 
preformed CSA in the assay system.  Cell culture and control solutions containing phorbol myristate 
had to be extensively dialyzed before assay since the drug was extremely active in stimulating CSA in a 
cell population resident in the bone marrow (Unpublished observations). 
* DMSO, dimethyl eulfexide. 
tion of granulocyte morphology, phagocytosis (16), receptors for immunoglobu- 
lin and complement, and lysozyme synthesis in a  myeloid leukemia cell line 
(17). 
The lipid A  fraction of LPS induces CSA  in PU5-1.8  cells, confirming the 
results of in vivo induction by Apte et al.  (18). CSA inducers acting on macro- 
phages are now expanded by these experiments to  include BCG,  tuberculin 
PPD,  zymosan, and phorbol myristate. Failure of Cline et al.  (3)  to observe 
increased CSA production by macrophages cultured with heat-killed Mycobacte- 
ria may be due to toxicity since it is specifically toxic to some macrophage tumor 
lines in culture (11). Dextran sulfate neither inhibited growth of PU5-1.8  cells 
nor stimulated CSA production. Other macrophage cell lines sensitive to growth 
inhibition by dextran sulfate (11) are induced by the polyanion to synthesize 
CSA (manuscript in preparation). Other macrophage properties stimulated by 
activators in the macrophage tumor cell lines include LAF (19), prostaglandin 
release (E. Rietschel, personal communication), elastase, collagenase (Z. Werb, 
personal communication), plasminogen activator (J.  Hamilton, manuscript in 
preparation),  and antibody-dependent cellular immunity against erythrocyte 
and tumor targets (20). 
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only  at  concentrations that  block  tumor cell  proliferation more than  50%. 
Growth inhibition may be a consequence of induced terminal differentiation, as 
seen  with  erythroblast and  myeloblast lines  (15-17). Thus,  extensive  DNA 
synthesis or cell cycling is not necessary for induction. Presence of  the inducer is 
necessary for a long time. Washing and resuspending cells in medium lacking 
LPS after 1 day greatly reduced their subsequent production of CSA (Fig. 1 B). 
There are few studies on the necessity for other cell types in macrophage 
activation. Results herein and those mentioned with macrophage tumor lines in 
culture provide evidence for inductive events occurring in the complete absence 
of other cell types. 
The granulocyte inhibitor of constitutive CSA production (13) failed to block 
LPS induction of CSA in PU5-1.8.  Inhibition of constitutive CSA production by 
granulocyte extract can be overcome by stimulation of cells with androgenic and 
anabolic steroids and LPS (21). This may allow for increased granulopoiesis in 
the  presence of high  concentrations of mature granulocytes as  in  acute in- 
flammatory reactions. 
Summary 
Monocyte tumor cell line PU5-1.8 does not normally produce colony-stimulat- 
ing  activity  (CSA)  required by granulocyte and  macrophage progenitors to 
proliferate and mature in agar. However, CSA is induced in the culture line by 
as little as 10 ng/ml endotoxic lipopolysaccharide (LPS), with maximum CSA 
production and release to  the medium between 2 and 3 days of incubation. 
Derived lipid A, but not alkali-treated LPS, is also active. Induction requires 
RNA and protein synthesis, but is not blocked by mitomycin C or Colcemid. 
Other inducers of CSA include Mycobacterium  Bacillus Calmette-Gudrin, tu- 
berculin protein preparation purified protein derivative, zymosan, and phorbol 
myristate. All inducing agents are specific inhibitors of  the monocyte tumor cell 
proliferation in vitro. Latex beads, another macrophage-activating agent, are 
rapidly phagocytosed by PU5-1.8  cells, but neither inhibit growth nor induce 
CSA. 
We thank M. Moore for support and advice, N. Williams and M. Dexter for criticism,  and S. 
Schrader for  expert technical assistance. 
Received for publication I1 April 1977. 
References 
1.  Chervenick, P. A., and A. F. LoBuglio. 1972. Human blood monocytes:  stimulators of 
granulocyte and mononuclear colony formation in  vitro.  Science  (Wash.  D.  C.). 
178:164. 
2.  Moore, M. A. S., N. Williams, and D. Metcalf. 1973. In vitro colony  formation by 
normal and leukemic  human hematopoietic  cells: interaction between  colony  forming 
and colony-stimulating  cells. J. Natl. Cancer Inst.  50:591. 
3.  Cline, M. J., B. Rothman, and D. W. Golde. 1974. Effect  ofendotoxin on the production 
of  colony-stimulating  factor  by human monocytes  and macrophages.  J. Cell. Physiol. 
84:193. 
4.  Eaves, A.  C.,  and  W.  R.  Bruce. 1974. In  vitro production of colony-stimulating 
activity. I. Exposure  of  mouse  peritoneal cells  to endotoxin. Cell Tissue Kinet. 7:19. 616  RALPH~  BROXMEYER,  AND  NAKOINZ  BRIEF  DEFINITIVE  REPORT 
5.  Ruscetti, F. W., and P. A. Chervenick. 1974. Release of colony-stimulating activity 
from monocytes by endotoxin and polyinosinic-polycytidylic acid. J. Lab. Clin. Med. 
83:64. 
6.  Alexander,  P.,  and R.  Evans.  1971. Endotoxin  and double-stranded RNA renders 
macrophages cytotoxic. Nat. New Biol. 232:75. 
7.  Hibbs, J.  B.,  Jr.  1974. Heterocytolysis by macrophages activated by Bacillus  Cal- 
mette-Gu~rin: lysosome exocytosis into tumor cells. Science (Wash. D. C.). 184:469. 
8.  Reed,  W.  P.,  and Z. J.  Lucas.  1975. Role of soluble toxin in macrophage-inhibited 
cultures of tumor cells. J. Immunol.  115:395. 
9.  Gronowicz, E., P. Biberfeld, B. Wahren, and A. Coutinho.  1976. Characterization of 
dextran sulfate-sensitive cells. Scand. J. Immunol.  5:573. 
10.  Ralph,  P.,  I.  Nakoinz,  and  W.  C.  Raschke.  1974. Lymphosarcoma cell  growth  is 
selectively inhibited  by B  lymphocyte mitogens:  LPS,  dextran  sulfate  and  PPD. 
Biochem. Biophys. Res. Commun.  61:1268. 
11.  Ralph,  P.,  and  I.  Nakoinz.  1977. Direct  toxic  effects  of immunopotentiators  on 
monocytic, myelomonocytic, and histiocytic or macrophage tumor cells in culture. 
Cancer Res. 37:546. 
12.  Ralph, P., and I. Nakoinz. 1974. Lipopolysaccharides inhibit lymphosarcomas of bone 
marrow origin. Nature  (Lond.).  249:883. 
13.  Broxmeyer, H. E., M. A. S. Moore, and P. Ralph. 1977. Cell-free granulocyte colony 
inhibiting activity derived from human polymorphonuclear neutrophils. Exp. Hema- 
tol.  (Copenh.).  5:87. 
14.  Ralph,  P.,  M.  S.  Moore, and K. Nilsson.  1976. Lysozyme synthesis by established 
human and murine histiocytic lymphoma cell lines. J. Exp. Med.  143:1523. 
15.  Friend,  C.,  and  W.  Scher.  1975. Stimulation  by dimethyl  sulfoxide  of erythroid 
differentiation and hemoglobin synthesis in  murine virus-induced  leukemic cells. 
Ann. N. Y. Acad. Sci.  243:155. 
16.  Ichikawa, Y., M. Maeda, and M. Horiuchi. 1975. Induction of differentiated functions 
which are reversibly suppressed by cytochalasin B. Exp. Cell Res. 9{}:20. 
17.  Krystosek, A., and L. Sachs.  1976. Control of lysozyme induction in the differentia- 
tion of myeloid leukemic cells. Cell. 9:676. 
18.  Apte, R. N., C. Galanos, and D. H. Pluznik. 1975. Lipid A, the active part of bacterial 
endotoxins in inducing serum colony stimulating activity and proliferation of splenic 
granulocyte/macrophage progenitor cells. J. Cell. Physiol.  87:71. 
19.  Lachman, L. B., and R. E. Handschumacher. 1976. Electromobility and purification 
of lymphocyte activating factor. Fed. Proc. 35:489. 
20.  Ralph,  P.,  and  I.  Nakoinz.  1977. Antibody-dependent  killing  of erythrocyte  and 
tumor targets  by monocyte-related cell lines:  enhancement by PPD  and  LPS.  J. 
Immunol.  In press. 
21.  Broxmeyer, H. E., and P. Ralph.  1977. In Vitro regulation of a  mouse myelomono- 
cytic leukemia line adapted to culture. Cancer Res. In press. 